ADH5 and acute myeloid leukemia: To test this, we subjected THP-1 cells, which are used as a model of acute monocytic leukemia (an AML sub-type), to treatment with HCHO, ASNase, or the ADH5 inhibitor N6022.40 Treatment of THP-1 cells with HCHO, N6022 or ASNase manifested inhibition of cell growth; treatment with mixtures of HCHO/N6022 and ASNase ablated growth under the tested conditions (Fig. 3e and S27†).